BIRC5 and ovarian carcinoma: Notably, our results indicated that the pharmacological inhibitor of survivin, YM155, effectively reduced survivin expression and the viability of ovarian cancer cells alone or in combination with cisplatin and paclitaxel, suggesting that YM155 itself may be promising as a therapeutic for ovarian cancer.